A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro and in vivo model systems

Inhibiting the disease progression in KRAS-driven cancers after diagnosis has been a difficult task for clinicians to manage due to lack of effective intervention/preventive therapies. KRAS-driven cancers depend on sustained KRAS-signaling. Although developing inhibitors of KRAS-signaling has proven...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Carcinog
Autors principals: Ganaie, Arsheed A., Siddique, Hifzur R., Sheikh, Ishfaq A., Parray, Aijaz, Wang, Lei, Panyam, Jayanth, Villalta, Peter W., Deng, Yibin, Konety, Badrinath R., Saleem, Mohammad
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334075/
https://ncbi.nlm.nih.gov/pubmed/32291806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.23200
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars